Regeneron stock holds below recent high as HSBC lifts target

Published on 09/14/2026 at 17:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock closed at USD 781.49 on Nasdaq on September 11, 2026, 8.9 percent below its 52-week high. HSBC has raised its price target on Regeneron stock to USD 920 with a Buy rating, highlighting Dupixent patent upside.

Fotorealistisches Biotech-Labor mit Forschern und Pipetten an sterilen Arbeitsplätzen — Regeneron Pharma US75886F1075 zeigt ein fotorealistisches Biotech-Labor mit Forschern bei sorgfältigen Pipettierarbeiten am sterilen Steriltisch, Illustration mit AI erstellt.

Regeneron Pharmaceuticals Inc. stock (ISIN US75886F1075) closed at USD 781.49 on Nasdaq on September 11, 2026, down 1.5 percent on the day and 8.9 percent below its 52-week high of USD 859.34, while still standing 44.4 percent above the 52-week low of USD 541.00.

HSBC raises price target to USD 920

As TradingView reported on September 14, 2026, HSBC lifted its price target for Regeneron stock to USD 920 from USD 800 and reiterated a Buy rating, implying roughly 17.7 percent upside from the September 11, 2026, close.

According to TradingView, HSBC’s more optimistic stance is tied to an estimated 70 percent probability that Sanofi and Regeneron will secure a two-year U.S. patent extension for their key drug Dupixent, potentially extending its market exclusivity to 2033.

Stock trading below 52-week peak ahead of investor event

In trading on September 11, 2026, Regeneron stock fluctuated between an intraday low of USD 780.81 and a high of USD 800.22 on Nasdaq, with volume of 443,972 shares, indicating active investor interest despite the 1.5 percent decline at the close.

The September 11, 2026, close of USD 781.49 left Regeneron stock 8.9 percent below its 52-week high of USD 859.34 and 44.4 percent above its 52-week low of USD 541.00, a range that shows the shares have already recovered substantially from their lows but still have room to move before matching prior peaks.

Per a recent overview cited by MarketBeat and summarized by Ad-hoc-news, the next major appearance for the company is at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, an event that can keep attention on Regeneron’s pipeline and commercial outlook.

Dupixent patent discussions shape the medium-term story

For shareholders, the Dupixent franchise is central to the medium-term narrative around Regeneron stock, and the roughly 70 percent chance of a U.S. patent extension to 2033 cited by TradingView would, if realized, support longer-lasting revenue protection than currently assumed.

Conversely, the same note highlighted that a less favorable outcome in patent proceedings would shorten the period of market exclusivity, increasing the risk of earlier-than-expected competition and potentially challenging the assumptions behind HSBC’s raised USD 920 price target.

Regeneron stock level and investor takeaway

As of the most recent completed Nasdaq session on September 11, 2026, Regeneron stock stood at USD 781.49, positioning the shares noticeably below their 52-week high yet well above the 52-week low, while analysts such as HSBC see scope for further gains if Dupixent’s patent life is extended.